Merck - Company Information
Merck & Co., Inc. is a global healthcare company that provides pharmaceuticals, vaccines, and animal health products, including prescription and over-...Read more
Headquarters
Contact
Linkedin
Company Size10,000+
Stock SymbolMRK
Websitemerck.com
TypePublic
Merck Technology Stack
Find prospects by the technologies they use. Use this section to learn more about key technologies and tools, tracked by 6sense, used by Merck
Merck Employee Profiles
Are you looking for the decision-makers at Merck? Get their email address, phone numbers, and other details from Linkedin or any website. Install and uncover Merck’s employee details in less than 30 secs.
Sign-up for 6sense Revenue AI™ for Sales
To find emails, direct dials, and more for prospects across the web.
Sign Up TodayDownload the 6sense Chrome Extension to get verified contact data of Merck employees
Install Now
Merck News & Press Releases
Sales prospecting needs to be timely and appropriate for the person and organization you are contacting. Following the most recent company news, alerts, and updates about the leads you are currently working on is the simplest and most convenient way to stay on top of them. Here are Merck latest news, alerts and updates.
Merck to acquire Caraway Therapeutics for up to USD 610 million
Rahway: Merck, known as MSD outside of the United States and Canada, and Caraway Therapeutics, Inc. have announced that the companies have entered into a definitive agreement under which
23 Nov 2023
Merck to Acquire Caraway Therapeutics, Inc.
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Caraway Therapeutics, Inc. announced today that the companies have entered into a definitive agreement under which Merck, through a subsidiary,
21 Nov 2023
Merck Announces Partnerships With BenevolentAI, Exscientia - Quick Facts
Merck announced two new strategic drug discovery collaborations aimed at harnessing AI-driven design and discovery capabilities. The
20 Sep 2023
Merck swings to loss as it books charge on $10.8 billion acquisition of Prometheus Biosciences
Merck & Co.'s stock was flat to lower on Tuesday after the company swung to a second-quarter loss as it booked a charge related to its $10.8 billion acquisition of Prometheus Biosciences Inc. The company swung to a net loss of $4.
2 Aug 2023
Merck finalizes $10.8B Prometheus acquisition
Robert Davis, chairman and CEO of the Rahway-based buyer, said the deal "accelerates our growing presence in immunology, augments our diverse pipeline and increases our ability to deliver patient value.
20 Jun 2023
Merck completes acquisition of Prometheus Biosciences
Merck, known as MSD outside of the United States and Canada, announced the completion of the Prometheus Biosciences, Inc. (Prometheus) acquisition. Prometheus is now a wholly-owned subsidiary of Merck and the common stock of Prometheus will no longer be ...
17 Jun 2023
FAQs for Merck
Explore frequently asked questions about Merck’s business, including founding details, header quarters, information on technology stack, industry listing, and other details.
Get instant access to B2B contact data across the web
Sign Up Today
